title: Ketonuria/ketonemia associated with the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in type 2 diabetes: A report of three cases from New Delhi, India.
authors.affiliation: Fortis C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology, New Delhi, India.
authors.forename: Amerta
authors.initials: A
authors.lastname: Ghosh
authors.affiliation: Fortis C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology, New Delhi, India.
authors.forename: Ritesh
authors.initials: R
authors.lastname: Gupta
authors.affiliation: Fortis C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology, New Delhi, India.|National Diabetes, Obesity and Cholesterol Foundation (N-DOC), New Delhi, India.|Diabetes Foundation (India), New Delhi, India.
authors.forename: Anoop
authors.initials: A
authors.lastname: Misra
mesh_terms: D001559:Benzhydryl Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D000068896:Canagliflozin / Q000009:adverse effects* / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005960:Glucosides / Q000009:adverse effects* / Q000627:therapeutic use; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D007194:India; D007662:Ketosis / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D051297:Sodium-Glucose Transporter 2 / Q000378:metabolism; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D001559:Benzhydryl Compounds; D001786:Blood Glucose; D000068896:Canagliflozin; D005960:Glucosides; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; C089180:SLC5A2 protein, human; C570240:empagliflozin